{"id":"NCT00957996","sponsor":"BioCryst Pharmaceuticals","briefTitle":"Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza","officialTitle":"A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-10","completion":"2011-08","firstPosted":"2009-08-13","resultsPosted":"2015-02-12","lastUpdate":"2015-02-12"},"enrollment":234,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Influenza","Cough","Sore Throat","Nasal Congestion","Myalgia","Headache","Fatigue"],"interventions":[{"type":"DRUG","name":"Peramivir","otherNames":[]},{"type":"DRUG","name":"Peramivir","otherNames":[]}],"arms":[{"label":"Peramivir 300 mg","type":"EXPERIMENTAL"},{"label":"Peramivir 600 mg","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.","primaryOutcome":{"measure":"Change From Baseline in Influenza Virus Titer (48 Hours)","timeFrame":"Baseline and 48 hours","effectByArm":[{"arm":"Peramivir 300 mg","deltaMin":-1.66,"sd":null},{"arm":"Peramivir 600 mg","deltaMin":-1.47,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":15},"locations":{"siteCount":110,"countries":["United States","Australia","Canada","Mexico","New Zealand","Puerto Rico"]},"refs":{"pmids":["23985625"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":114},"commonTop":["Constipation","Diarrhoea","Hypokalaemia","Nausea","Oedema Peripheral"]}}